Ex vivo simulation of cardiopulmonary bypass with human blood for hemocompatibility testing

Abstract

Object:

Experimental circuits for biomaterial surface testing are frequently limited by the tested blood volume, composition of the circuit, flow conditions and the use of animal blood. This report describes an ex vivo set-up for simulated cardiopulmonary bypass with human blood perfusion. We investigated the clinical generalizability of the observed effects on hematological and metabolic parameters and the hemocompatibility of the system.

Methods:

The simulated cardiopulmonary bypass circuit consisted of a heparin-coated tubing system connected to an oxygenator and a venous reservoir. Normothermic flow of blood obtained from healthy donors was maintained at 2.4 L/min/m² by a roller pump. Heparin was dosed to obtain a target activated clotting time (ACT) ⩾500 s. Blood was drawn at baseline and 0, 10, 60 and 120 minutes following the initiation of blood flow to determine hematological and metabolic parameters and the hemocompatibility of the extracorporeal system. Data were analyzed using repeated measures ANOVA.

Results:

Two hours of blood perfusion resulted in a small, but clinically unimportant reduction in hematocrit, whereas hemoglobin levels and red blood cell, platelet and leukocyte counts remained stable. There was a significant increase in ACT throughout the experiment. While pO₂ levels and the pH remained unaltered during the experiment, pCO₂ values decreased from 51 ± 6 mmHg at T0 to 41 ± 3 mmHg at T120 (p<0.001). Simulated cardiopulmonary bypass induced a two-fold increase in C3a (p=0.001) while tissue factor was decreased from 44 ± 14 pg/mL at T0 to 38 ± 13 pg/mL at T120 (p=0.009). Levels of CD40L, prothrombin fragment 1+2, β-thromboglobulin and factor VIIa remained stable over time.

Conclusion:

The ex vivo set-up for simulated cardiopulmonary bypass mimicked the clinical cardiosurgical setting. Exposure of fresh donor blood to the extracorporeal circuit showed a good hemocompatibility, indicated by maintained hematological parameters and a mild immune response.

Keywords

cardiopulmonary bypass hemostasis biosurface coating heparin

Get full access to this article

View all access options for this article.

References

Baufreton

Kirsch

Loisance

. Measures to control blood activation during assisted circulation. Ann Thorac Surg 1998; 66: 1837–1844.

Mollnes

. Complement and biocompatibility. Vox Sang 1998; 74: 303–307.

Paparella

Brister

Buchanan

. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873–1881.

Jacobs

De Somer

Vandenplas

. Active or passive bio-coating: does it matter in extracorporeal circulation? Perfusion 2011; 26: 496–502.

De Somer

. Optimization of the perfusion circuit and its possible impact on the inflammatory response. J Extra Corpor Technol 2007; 39: 285–288.

Te Velthuis

Baufreton

Jansen

PGM

. Heparin coating of extracorporeal circuits inhibits contact activation. J Thorac Cardiovasc Surg 1997; 114: 117–122.

Seyfert

Biehl

Schenk

. In vitro hemocompatibility testing of biomaterials according to the ISO 10993–4. J Biomed Biotechnol 2007; 10: 29464.

Stevens

Aldenhoff

van der Veen

. Bioengineering of improved biomaterials coatings for extracorporeal circulation requires extended observation of blood-biomaterial interaction under flow. Biomol Eng 2002; 19: 91–96.

Van Oeveren

Tielliu

de Hart

. Comparison of modified chandler, roller pump, and ball valve circulation models for in vitro testing in high blood flow conditions: application in thrombogenicity testing of different materials for vascular applications. Int J Biomater 2012; 2012: 673163.

10.

Gong

Larsson

Ekdahl

. Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol 1996; 16: 222–229.

11.

Münch

Wolf

Gruffaz

. Use of simple and complex in vitro models for multiparameter characterization of human blood-material/device interactions. J Biomater Sci Polym Ed 2000; 11: 1147–1163.

12.

Kessler

Grau

Gronchi

. Comparison of porcine and human coagulation by thrombelastometry. Thromb Res 2011; 128: 477–482.

13.

Teligui

Dalmayrac

Mabilleau

. An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose. Interact Cardiovasc Thorac Surg 2014; 18: 763–769.

14.

Siller-Matula

Plasenzotti

Spiel

. Interspecies differences in coagulation profile. Thromb Haemost 2008; 100: 397–404.

15.

Korn

Fisher

Livingston

. The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation. J Thorac Cardiovasc Surg 1996; 111: 1073–1084.

16.

Wendel

Heller

Gallimore

. Heparin-coated devices and high-dose aprotinin optimally inhibit contact system activation in an in vitro cardiopulmonary bypass model. Immunopharmacology 1996; 32: 128–130.

17.

Larm

Larsson

Olsson

. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983; 11: 161–173.

18.

Johnson

Curry

Cahalan

. In vitro assessment of blood compatibility: residual and dynamic markers of cellular activation. J Biomater Appl 2013; 27: 925–936.

19.

Morizumi

Hiramatsu

Matsuzaki

. Early heparin administration attenuates tissue factor-mediated thrombin generation during simulated cardiopulmonary bypass. J Card Surg 2014; 29: 35–40.

20.

Nilsson

Ekdahl

Mollnes

. The role of complement in biomaterial-induced inflammation. Mol Immunol 2007; 44: 82–94.

21.

Weber

Wendel

Ziemer

. Quality assessment of heparin coatings by their binding capacities of coagulation and complement enzymes. J Biomater Appl 2000; 15: 8–22.

22.

Pekna

Nilsson

Nilsson-Ekdahl

. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol 1993; 91: 404–409.

23.

Tayama

Hayashida

Akasu

. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Artif Organs 2000; 24: 618–623.